| __timestamp | BioMarin Pharmaceutical Inc. | Dyne Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 1145000000 |
| Thursday, January 1, 2015 | 152008000 | 2028000000 |
| Friday, January 1, 2016 | 209620000 | 2281000000 |
| Sunday, January 1, 2017 | 241786000 | 2932000000 |
| Monday, January 1, 2018 | 315264000 | 24000 |
| Tuesday, January 1, 2019 | 359466000 | 271000 |
| Wednesday, January 1, 2020 | 524272000 | 700000 |
| Friday, January 1, 2021 | 470515000 | 1088000 |
| Saturday, January 1, 2022 | 483669000 | 3345000 |
| Sunday, January 1, 2023 | 577065000 | 2461000 |
| Monday, January 1, 2024 | 580235000 |
Data in motion
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. BioMarin Pharmaceutical Inc. and Dyne Therapeutics, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. BioMarin has demonstrated a steady increase, with a notable 345% rise from 2014 to 2023. In contrast, Dyne Therapeutics experienced a dramatic fluctuation, peaking in 2017 before a significant drop in subsequent years. By 2023, Dyne's cost of revenue had decreased by over 99% from its 2017 high. This divergence highlights BioMarin's consistent growth strategy, while Dyne's volatility suggests a period of restructuring or strategic pivot. Understanding these trends provides valuable insights into the operational efficiencies and strategic directions of these biotech leaders, offering investors and industry analysts a clearer picture of their financial health and market positioning.
Bristol-Myers Squibb Company vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Zoetis Inc. vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: GSK plc and BioMarin Pharmaceutical Inc.
Comparing Cost of Revenue Efficiency: GSK plc vs Dyne Therapeutics, Inc.
Cost of Revenue Trends: Viatris Inc. vs Dyne Therapeutics, Inc.
BioMarin Pharmaceutical Inc. vs Jazz Pharmaceuticals plc: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Corcept Therapeutics Incorporated
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for HUTCHMED (China) Limited and Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Dyne Therapeutics, Inc.'s Expenses
Dyne Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored